SPY357.46+2.13 0.60%
DIA295.89+3.36 1.15%
IXIC11,880.63+25.66 0.22%

9 Meters Biopharma Announces Preclinical Data For NM-102 Gut Microbiome Modulator

  NM-102, a novel next-generation microbiome modulator, shows positive effect in an aggressive immune checkpoint inhibitor failure melanoma model IND-enabling planning underway RALEIGH, NC / ACCESSWIRE /

· 11/16/2020 07:37

 

  • NM-102, a novel next-generation microbiome modulator, shows positive effect in an aggressive immune checkpoint inhibitor failure melanoma model
  • IND-enabling planning underway

RALEIGH, NC / ACCESSWIRE / November 16, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced preliminary results from a collaboration with Gustave Roussy, Villejuif, France (a 14-months research project initiated in March 2019), using NM-102, a novel peptide that modulates intestinal permeability and the gut microbiome.

"We are pleased to show through this collaboration how our novel peptide, NM-102, can fit within the complex interactions of the gut microbiome and immunosurveillance. We intend to continue to advance research in this space to better understand this promising area of immunomodulation via the gut," said Patrick H. Griffin, M.D., chief medical officer of 9 Meters Biopharma.

NM-102 is a long-acting, degradation-resistant peptide, believed to be gut-restricted, and presumed to prevent gut microbial metabolites and antigens from trafficking into systemic circulation. The researchers found that NM-102 was effective alone or when combined with immune checkpoint inhibitors (ICIs) in a pre-clinical transgenic mouse model of spontaneous aggressive skin melanoma. Furthermore, the combination of NM-102 with ICIs improved survival compared to ICIs alone.

The work focused on intestinal microbiome dysbiosis and its effects on responses to chemotherapy and ICIs, such as CTLA-4- and PD-1-based immunotherapies, thought to be attributed to abnormal gut microbial composition.

The researchers used preclinical oncology models to understand how the therapeutic effect of ICIs, such as antibodies to CTLA-4 and PD-1, is modulated by preventing bacterial antigens, toxins and certain metabolites from interacting with the host immune system. This transgenic mouse model is an aggressive melanoma tumor model that only responds to the combination of ICIs, such as anti-PD-1 and anti-CTLA-4.

The Company intends to move forward with an IND-enabling pathway to further develop NM-102.